Millions of Americans are not taking their GLP-1 drugs as prescribed
CDC data reveals nearly half of U.S. GLP-1 users are altering prescribed dosing regimens, with cost cited as the primary driver especially among younger adults.
17 trends tracked about this subject — the full history, oldest to newest below.
CDC data reveals nearly half of U.S. GLP-1 users are altering prescribed dosing regimens, with cost cited as the primary driver especially among younger adults.
Internal medicine physician Dr. Frank Dumont warns that stopping GLP-1 medications like Ozempic and Zepbound carries six rebound risks, including rapid weight regain, loss of cardiovascular protection, and worsening mental health.
Eli Lilly's Zepbound shows promise for knee pain relief alongside weight loss in new Phase 3b data, while Taltz combination therapy demonstrates durable psoriatic arthritis outcomes.
Two case reports describe men who developed psychosis after stopping tirzepatide, adding to questions about the psychiatric effects of discontinuing GLP-1 drugs.
A 40-week study found that resistance training helped people taking tirzepatide lose 25% less lean tissue while improving strength by 10%.
19 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Federal regulators face mounting scrutiny as unapproved weight-loss drugs and new safety warnings enter public focus.
3 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
2 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Eli Lilly reports that its new combination obesity regimen, EloraTZP, outperformed tirzepatide in a mid-stage clinical trial.
8 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
Recent coverage examines rapid weight regain after discontinuing GLP-1 medications like Ozempic, semaglutide, and tirzepatide.
Growing concerns emerge over the 'Ozempidemic' as users report intense cravings and safety risks associated with GLP-1 weight-loss medications.
5 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
8 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
9 news sources are covering this Health story right now — PULSE is tracking how fast it spreads.
Researchers screening 6,000 existing medications have identified potential anti-aging properties in common drugs, including GLP-1 weight loss treatments.